GlassScriptPhysician profile
Judith M Gilmore
NPI 1114003209
$11,130.39
in general payments reported to CMS, 2019-2025
29 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,030 · 2020: $1,162 · 2021: $2,352 · 2022: $2,174 · 2023: $1,733 · 2024: $1,068 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,393 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,393.11 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,163.60 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,985.83 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $1,093.29 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $778.47 | 2019-2024 | Mounjaro, Jardiance, Baqsimi |
| Corcept Therapeutics | $741.25 | 2021-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $597.24 | 2019-2021 | |
| Abbvie INC. | $556.51 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $485.87 | 2022-2025 | |
| Amarin Pharma, INC. | $395.95 | 2019-2022 | |
| Amgen INC. | $386.55 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $363.72 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $316.60 | 2019-2020 | |
| Novo Nordisk INC | $306.50 | 2019-2025 | Ozempic |
| Ultragenyx Pharmaceutical INC. | $155.29 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $126.97 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $122.85 | 2019 | |
| Amneal Pharmaceuticals LLC | $122.15 | 2019-2024 | Unithroid |
| Mannkind Corporation | $98.33 | 2020-2021 | |
| Valeritas, INC. | $72.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $48.29 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $44.19 | 2019 | |
| Merck Sharp & Dohme LLC | $25.26 | 2019 | |
| Acella Pharmaceuticals, LLC | $24.63 | 2023 | NP Thyroid 60 |
| Shire North American Group INC | $22.93 | 2019 | |
| Ibsa Pharma INC. | $21.85 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.22 | 2019 | |
| Emergent Biosolutions INC. | $18.75 | 2019 | |
| Gilead Sciences, INC. | $17.84 | 2019 | |
| Dexcom, INC. | $17.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Gilmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.